Biotechnology

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

December 19, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that the Company has completed payment of all outstanding variable convertible debt obligations. On August 30, 2023, the Company and the Noteholder YA II...

Read more

Canopus BioPharma Inc., dba Blue Heaven Coffee Inc., Announces Amendment to PepsiCo (Nasdaq: PEP) Distributor Partnership Beverage Agreement

December 19, 2023 7:00 AM

LAS VEGAS, NV / ACCESSWIRE / December 19, 2023 / Operating as Blue Heaven Coffee Inc. (BHC), Canopus Biopharma Inc. (OTC PINK:CBIA) is thrilled to announce a fully executed amendment to its original distributor partnership beverage agreement with the world-renowned beverage company, PepsiCo, Inc. (Nasdaq: PEP). The original agreement (announced to markets on September 7, 2023) established PepsiCo as the exclusive cold-beverage provider for BHC's...

Read more

BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research

December 19, 2023 4:00 AM

German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies. HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan....

Read more

Shaperon Completes Investigator Meeting in the U.S. for Atopic Dermatitis Treatment 'HY209gel'

December 18, 2023 9:30 AM

SEOUL, SOUTH KOREA / ACCESSWIRE / December 18, 2023 / Shaperon Inc. (378800.KQ), a KOSDAQ-listed, Korean biotech company developing innovative immune drugs, has announced the successful completion of an investigator meeting for the Phase 2 clinical trial for the atopic dermatitis treatment ‘HY209gel' in Dallas, Texas, USA on December 9, 2023. The investigator meeting was organized to introduce and discuss the operational progress and future...

Read more

CDBT Registers Magistrates Court of Queensland Judgments against Kenneth Maciora / Empire Relations Group

December 16, 2023 6:30 PM

ARUNDEL, AUSTRALIA / ACCESSWIRE / December 16, 2023 / China Dasheng Biotechnology Co. (OTC Pink: CDBT) advises that it has been issued 2 Judgements, $17,129.13 and $17,066.59 in its favor against Kenneth Maciora and Empire Relations Group, Inc., and those Judgements have been registered with the Magistrates Court of Queensland on November 29, 2023. Background: As disclosed on October 9, 2023, CDBT formally terminated the China Dasheng...

Read more

Edesa Biotech Reports Fiscal Year 2023 Results

December 15, 2023 4:10 PM

TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business. During the year, Edesa reported favorable results from two clinical studies and achieved multiple regulatory and...

Read more

enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium

December 14, 2023 11:30 AM

- Interviews with patients from the VenoValve® pivotal study - Materials now available on the Company's website IRVINE, CA / ACCESSWIRE / December 14, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it has posted Company highlights and materials from the recently held 50th Annual VEITH Symposium on the enVVeno website....

Read more

Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview

December 14, 2023 10:00 AM

Company focused on advancing novel personalized cancer vaccines to overcome tumor resistance to immunotherapies like checkpoint inhibitors; and first-in-class bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs) to modulate their immunosuppressive effects on the tumor microenvironment Company on track to initiate pivotal Phase 3 study of lead program, IFx-2.0, in Merkel Cell Carcinoma (MCC) in 2024...

Read more

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

December 14, 2023 8:15 AM

Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity Reduction PF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024 SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its most recent study...

Read more

Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)

December 14, 2023 7:00 AM

Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences' cannabinoid-based medicine for the treatment of Parkinson's disease. LAS VEGAS, NV / ACCESSWIRE / December 14, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, will be featured on Worldwide Business with kathy ireland® on Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business...

Read more

Moolec Science Presents First Quarter Fiscal Year 2024 Business Update

December 14, 2023 6:00 AM

LUXEMBOURG / ACCESSWIRE / December 14, 2023 / Moolec Science SA (NASDAQ:MLEC), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the first quarter of Fiscal Year 2024 ended September 30, 2023. The main highlights of Moolec's business update are as follows: GLASO: Moolec harvested 35 hectares with a yield of 1.8 tons per hectare....

Read more

MindMics, Inc. Honored with Two CES(R) 2024 Innovation Honoree Awards

December 14, 2023 3:00 AM

CAMBRIDGE, MA / ACCESSWIRE / December 14, 2023 / MindMics, the inventor of infrasonic sound-based technology for in-ear earphones and hearables, today announced that it has been named a CES® 2024 Innovation Awards Honoree in the digital health and wearables technology categories for the MindMics Heart Health System. This year's CES Innovation Awards program received a record number of over 3000 submissions. The announcement was made ahead of CES...

Read more

AppYea Provides Year-End Letter to Shareholders Recapping Key Achievements and Sharing Outlook for 2024

December 13, 2023 6:20 AM

GAN YAVNE, ISRAEL / ACCESSWIRE / December 13, 2023 / AppYea Inc. (OTCQB:APYP), focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, today provided the following letter to shareholder from the Company's CEO, Adi Shemer: To our valued shareholders, I am thrilled to share the remarkable strides our company has made throughout the past year. This period has undeniably marked a pivotal turning point...

Read more

Disrupting T-Cell AI Stack by QuBind.com Enables - AI-Accelerated T-Cell Therapy Discovery and Next Gen Liquid Biopsies

December 12, 2023 11:20 AM

NEW YORK, NY / ACCESSWIRE / December 12, 2023 / QuBind, a startup at the forefront of T-cell therapy innovation, announces a significant development in immunotherapy with its AI-integrated platform. This platform enhances the accuracy and safety of T-cell therapies, addressing key challenges in the field. QuBind's approach utilizes a novel AI stack to analyze immune system responses, facilitating the discovery of effective treatments and...

Read more

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

December 12, 2023 10:00 AM

Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the completion of a Human Factors Study, whose objective was to assess the technology component developed...

Read more

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider

December 12, 2023 9:15 AM

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces its partnership with Idea Evolver (IE), a Technology platform for Rx-to-OTC switches and digital...

Read more

Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.

December 12, 2023 9:00 AM

MIAMI, FL / ACCESSWIRE / December 12, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of treatments for neurological diseases, is thrilled to announce the appointment of Dr. Neilank K. Jha as its new Executive Chairman and Chief Executive Officer. Dr. Jha is recognized for his extensive experience and wealth...

Read more

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

December 11, 2023 8:01 AM

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single dose TH104 was well tolerated with no unexpected treatment-emergent adverse events comparable to previous phase 1 studies Company funded into early 2025 and expects bridging PK data in the US and Phase 2a results for chronic pruritus in primary biliary cholangitis (PBC) in 2024 BRIDGEWATER,...

Read more

Bionoid Pharma Inc. Provides Update on Binding Letter of Intent to Acquire Global Alerts Corp.

December 8, 2023 7:00 AM

"Paving the Way for a Safer World Through Advanced Emergency Communications" TORONTO, ON / ACCESSWIRE / December 8, 2023 / Bionoid Pharma, Inc. ("BINP" or the "Company") (OTC PINK:BINP) is pleased to announce a significant development in its ongoing partnership negotiations with Global Alerts Corp. ("Global Alerts"). After successfully extending the effective period of the non-binding Letter of Intent ("LOI") and its exclusivity provisions,...

Read more

FREEDOM HOLDINGS (FHLD) SHAREHOLDER UPDATE; 15c211 Nears Final Approval from FINRA 

December 8, 2023 6:00 AM

CHATSWORTH, CA / ACCESSWIRE / December 8, 2023 / Freedom Holdings, Inc. aka Freedom Acquisition Corp. (OTC PINK:FHLD) ("FHLD" or the "Company") is pleased to announce following Company Update: Freedom Holdings waiting on 15c211 final approval from FINRA. This past summer, Freedom Holdings had worked diligently with a Glendale Securities over the past several months to seek FINRA approval of its 15C-211. We expect having that approval any day...

Read more